Ossifix manufactures its Javelin Hex Allograft Pin from 100% select allograft bone. It is applicable for small bone, extremities, and sports medicine markets that also has applications in the craniofacial, spine and oral surgery procedures. Resorbable implant technology is readily accepted and used in today’s market, both domestically and globally.
Surgeon, Dr.
Surgeries using prior technology for a surgical bunionectomy involved the resection of the metatarsal. The bone is realigned utilizing metal plates, screws, wire and other hardware to stabilize the resection. With current techniques, fixation hardware requires recovery that can be long, painful and, often lasts up to a year with any metallic hardware remaining in place for life. Recovery can require long-term immobilization and pain management for some patients. Patients are often told not to bear-weight on the foot for six or more weeks. Patients are typically required to wear a fracture cast/boot for one to three months post-surgery. Extensive physical therapy is required to recondition the foot, ankle and calf due to months of non-use. Custom shoe inserts might also be required permanently.
With Ossifix Orthopedics allograft implants, the design of the Javelin bone pin reduces surgical time by as much as 50% making it faster and more efficient than even some minimally invasive bunionectomy techniques. Typically, surgeries using The Javelin pin take 20-22 minutes and are conducted on an outpatient basis with patients being able to ambulate relatively pain free the next day. Generally speaking, callus formation should begin and show up on x-rays within 3-4 weeks with complete reabsorption within 6-8 weeks. There is no metal implant or screw to worry about as the Javelin pin is manufactured completely from human allograft cortical bone and is completely absorbed; becoming a part of body. There is little to no risk of a bio-immune response or implant rejection as the implant is made of 100% human tissue.
Case studies are being conducted on current patients to further enhance surgical procedures and monitor recovery time. Initial surgeons will be releasing case studies to be peered reviewed and will begin speaking engagements at medical conferences in the coming months.
The Ossifix Orthopedics line of products will compete in one of the fastest growing, emerging markets, specifically, the resorbable implant market, in three distinct surgical segments; orthopedic, sports medicine and dental. Ossifix products are designed to be used in hospitals, ambulatory surgical centers, and specialty clinics. Distribution is scheduled throughout
Ossifix Orthopedics products have been launched in
Manufactured in
For more information about Ossifix Technologies go here: https://ossifixtech.com/
About
The firm is located in the
For more information visit www.uatgroup.com
Investor and Media Contact: info@uatgroup.com
NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.
Forward-Looking Information
This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of
Source:
2022 GlobeNewswire, Inc., source